leadf
logo-loader
viewInternational Consolidated Airlines Group

British Airways owner IAG downgraded ahead of painful rights issue

Analysts at Davy Research predicted the €2.75bn fundraising will be “at least 50% dilutive” and assumed a “slower recovery versus the current capacity planning scenario” which is expected to drop 35% compared to 2019

International Consolidated Airlines Group - British Airways owner IAG downgraded ahead of painful rights issue

British Airways owner International Consolidated Airlines Group SA (LON:IAG) has been downgraded to ‘neutral’ from ‘outperform’ by analysts at Davy Research as they worked out the effects of the company’s proposed “painful rights issue” announced at the end of July.

In a note on the airline sector on Wednesday, Davy’s analysts predicted the €2.75bn fundraising will be “at least 50% dilutive” and assumed a “slower recovery versus the current capacity planning scenario” which is expected to drop 35% compared to 2019.

READ: British Airways owner IAG in €2.75bn rights call as losses top €4bn

Announcing the rights issue on July 31, IAG said the money will provide support for its balance sheet and help it withstand a prolonged downturn in air travel due to coronavirus restrictions.

Willie Walsh, IAG’s chief executive, said the money would put it in the strongest position possible ahead of a recovery, though he added he does not expect this now to be until 2023.

IAG’s downgrade also formed part of the broker’s wider assessment of the airline sector, predicting that inter-continental and corporate travel “look certain to recover later than continental/leisure travel”.

“We don’t know yet whether their restructurings will enhance or weaken competitive positioning when we see other global airlines restructuring”, Davy said.

Shares in IAG were 2.1% lower at 214.2p in mid-morning trading.

Quick facts: International Consolidated Airlines Group

Price: 91 GBX

LSE:IAG
Market: LSE
Market Cap: £18.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO plays 'pivotal role' after announcing £2m extension to Huntington's...

IXICO PLC's (LON:IXI) Lammert Albert talks to Proactive London about the £2m extension to a contract to provide additional imaging services for a pivotal Huntington's disease (HD) study. Albert describes this as a 'strong suit' having started very early and now carrying out a Phase III study...

33 minutes ago

2 min read